CN101663308A - N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 - Google Patents

N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 Download PDF

Info

Publication number
CN101663308A
CN101663308A CN200780048992A CN200780048992A CN101663308A CN 101663308 A CN101663308 A CN 101663308A CN 200780048992 A CN200780048992 A CN 200780048992A CN 200780048992 A CN200780048992 A CN 200780048992A CN 101663308 A CN101663308 A CN 101663308A
Authority
CN
China
Prior art keywords
dcp
administering
patient
effective amount
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780048992A
Other languages
English (en)
Chinese (zh)
Inventor
P·莫赫诺
W·普夫莱德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SanRX Pharmaceuticals Inc
Original Assignee
SanRX Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SanRX Pharmaceuticals Inc filed Critical SanRX Pharmaceuticals Inc
Publication of CN101663308A publication Critical patent/CN101663308A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN200780048992A 2006-10-30 2007-10-30 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 Pending CN101663308A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86354706P 2006-10-30 2006-10-30
US60/863,547 2006-10-30

Publications (1)

Publication Number Publication Date
CN101663308A true CN101663308A (zh) 2010-03-03

Family

ID=39344907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780048992A Pending CN101663308A (zh) 2006-10-30 2007-10-30 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法

Country Status (7)

Country Link
US (2) US7662820B2 (enExample)
EP (1) EP2094715B1 (enExample)
JP (1) JP2010508349A (enExample)
CN (1) CN101663308A (enExample)
CA (1) CA2668262A1 (enExample)
ES (1) ES2394227T3 (enExample)
WO (1) WO2008054793A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685780T3 (es) * 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
EP1726952A4 (en) * 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
EP2094715B1 (en) * 2006-10-30 2012-08-29 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
CA2712118A1 (en) * 2008-01-18 2009-07-23 Sanrx Pharmaceuticals, Inc. Pterin based therapies for inflammatory conditions
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
WO2013116238A1 (en) * 2012-01-30 2013-08-08 Sanrx Pharmaceuticals, Inc. Calcium folate (cafolate) and therapeutic methods based thereon
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358953B1 (en) * 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2094715B1 (en) * 2006-10-30 2012-08-29 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358953B1 (en) * 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents

Also Published As

Publication number Publication date
CA2668262A1 (en) 2008-05-08
EP2094715A4 (en) 2010-04-28
US20100105692A1 (en) 2010-04-29
EP2094715B1 (en) 2012-08-29
WO2008054793A2 (en) 2008-05-08
US20080166355A1 (en) 2008-07-10
WO2008054793A3 (en) 2008-08-28
ES2394227T3 (es) 2013-01-23
JP2010508349A (ja) 2010-03-18
US7662820B2 (en) 2010-02-16
EP2094715A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
US7662820B2 (en) Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
JP6312919B2 (ja) 細菌株を含む組成物
JP6837700B2 (ja) ジピベフリンの使用方法
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
BR112020017090A2 (pt) Imunoterapias relacionadas com microbioma
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
WO2015161762A1 (zh) 环二核苷酸cGAMP在抗肿瘤中的应用
KR20170124604A (ko) 암 치료를 위한 ｈｄａｃ 억제제 및 항ｐｄ-1 항체의 조합
US20190262267A1 (en) Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
CN102573826A (zh) 用于治疗癌症的喷他脒组合
CN102119214A (zh) 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物
WO2017162055A1 (zh) 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
Zou et al. An intermediate-crystalline phase manganese nanoadjuvant potently activates cGAS-STING signaling and antitumor immunity via immunometabolism normalization
JP4855250B2 (ja) 抗腫瘍作用を有する組成物
Yin et al. Ultrasound Responsive Mn/Se‐Nanozyme as PANoptosis Initiators for Bladder Cancer Immunotherapy
JPH0617304B2 (ja) 制癌剤
US20200237904A1 (en) Methods and Compositions Useful for Treating Cancer
WO2008066783A2 (en) Therapeutic materials and methods
CN116350795B (zh) 一种线粒体靶向非诺贝特酸、构建方法及应用
HK1139952A (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
Chen et al. Absorption characteristics of novel compound calcium carbonate granules: effects of gastric acid deficiency and exogenous weak acids
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
CN104434948A (zh) 一种抗胰腺癌的药物组合物及其应用
JP7624241B2 (ja) がんの予防または治療用薬学的組成物
EP4226939A1 (en) Novel use of mycobacterium tuberculosis extract

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139952

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139952

Country of ref document: HK